EMA Authorised: Alunbrig (brigatinib) — Takeda Pharma A/S

View source ↗

Summary

The EMA has authorised Alunbrig (brigatinib) for non-small cell lung cancer, with Takeda Pharma A/S as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Takeda Pharma A/S. Decision date: 13/03/2025